Vital Products Health VPH 2023 Investor Presentation

Canadian specialty pharmaceutical company with 8X revenue growth from 2020-2023, focusing on licensing and acquiring Canadian rights to commercial prescription drugs. The company operates with a pan-Canadian presence, 12 commercialized products across 3 therapeutic areas, and 6 core high-growth assets including REDESCA, ENERZAIR, ATECTURA, ALLERJECT, XIIDRA, and SIMBRINZA.